About Dynavax Technologies Corporation
https://www.dynavax.comDynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
CEO
Ryan Spencer
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-11-10 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 184
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
William Blair
Market Perform
Goldman Sachs
Sell
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:21.9M
Value:$341.69M
BLACKROCK, INC.
Shares:16.25M
Value:$253.49M
DEEP TRACK CAPITAL, LP
Shares:15.73M
Value:$245.33M
Summary
Showing Top 3 of 330
About Dynavax Technologies Corporation
https://www.dynavax.comDynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $94.88M ▼ | $59.2M ▼ | $26.93M ▲ | 28.38% ▲ | $0.23 ▲ | $31.89M ▲ |
| Q2-2025 | $95.44M ▲ | $66.98M ▼ | $18.72M ▲ | 19.62% ▲ | $0.16 ▲ | $24.63M ▲ |
| Q1-2025 | $68.16M ▼ | $78.03M ▲ | $-96.1M ▼ | -140.98% ▼ | $-0.77 ▼ | $-94.44M ▼ |
| Q4-2024 | $72.03M ▼ | $60.25M ▲ | $7.05M ▼ | 9.79% ▼ | $0.06 ▼ | $12.27M ▼ |
| Q3-2024 | $80.63M | $57.46M | $17.59M | 21.82% | $0.13 | $23.57M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $647.82M ▲ | $946.51M ▲ | $412.37M ▼ | $534.14M ▲ |
| Q2-2025 | $613.73M ▼ | $918.45M ▼ | $424.29M ▲ | $494.16M ▼ |
| Q1-2025 | $661.34M ▼ | $945.93M ▼ | $414.99M ▲ | $530.94M ▼ |
| Q4-2024 | $713.83M ▼ | $986.26M ▼ | $389.46M ▲ | $596.8M ▼ |
| Q3-2024 | $763.99M | $1.06B | $380.56M | $681.43M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $26.93M ▲ | $33.83M ▲ | $27.32M ▼ | $-61K ▲ | $61.15M ▲ | $32.59M ▲ |
| Q2-2025 | $18.72M ▲ | $23.43M ▲ | $94.79M ▲ | $-71.92M ▼ | $47.41M ▲ | $21.98M ▲ |
| Q1-2025 | $-96.1M ▼ | $-19.64M ▼ | $6.91M ▼ | $-31.88M ▲ | $-44.15M ▼ | $-23.57M ▼ |
| Q4-2024 | $7.05M ▼ | $53.01M ▲ | $23.37M ▲ | $-98.88M ▼ | $-23.45M ▼ | $49.53M ▲ |
| Q3-2024 | $17.59M | $19.47M | $-15.46M | $2.48M | $6.84M | $18.12M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 H E P L I S A V B | $70.00M ▲ | $60.00M ▼ | $90.00M ▲ | $90.00M ▲ |
 Other Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $70.00M ▲ | $90.00M ▲ | $70.00M ▼ | $90.00M ▲ |
CEO
Ryan Spencer
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-11-10 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 184
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
William Blair
Market Perform
Goldman Sachs
Sell
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:21.9M
Value:$341.69M
BLACKROCK, INC.
Shares:16.25M
Value:$253.49M
DEEP TRACK CAPITAL, LP
Shares:15.73M
Value:$245.33M
Summary
Showing Top 3 of 330